Do you want to skip to content? Skip to content
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Convatec False /oidc-signin/en-us/

Most visited pages

Reports, results and presentations
Contact Us Convatec Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

05 March 2021

Download press release

PDF Download

 

Solid growth and good strategic progress 

table

 

FY 2020 key highlights:

  • Improved revenue growth: +3.7% reported growth and +4.0% on a constant currency2
  • Attractive diversified portfolio providing resilience during the pandemic.
    • FY20 performance driven by strong growth in Infusion Care and Continence & Critical Care offsetting limited growth in Ostomy Care and decline in Advanced Wound Care.
    • Q4 revenue performance reflected the impact of the latest COVID-19 resurgence late in the year. This was driven primarily by better than expected revenues in Continence & Critical Care.
  • Continued investment for growth: Adjusted1 EBIT margin of 18.5% (2019: 19.4%) in line with the latest guidance.
  • Strong adjusted free cash flow1: $347 million (2019: $397 million) and adjusted cash conversion1 of 90% (2019: 98%).
  • Strengthened balance sheet: Reduction in leverage to 2.0x Net Debt/Adjusted EBITDA1 (2019: 2.5x).
  • Proposed dividend of 3.983 cents to take FY dividend to 5.7 cents, in line with prior year.

 

Good operational and strategic progress as we pivot to sustainable and profitable growth:

  • Effective response to COVID-19 – safeguarding the health and wellbeing of our people, addressing customer needs and strengthening our supply chain.
  • Further positive operational progress – adjusted gross margin1 increased from 59.0% to 59.5% or $1,127 million.
  • Continued to make good progress with our FISBE (Focus, Innovate, Simplify, Build, Execute) strategy. Achievements in the year include:
    • Strengthening the leadership team; embedding the new operating model; increasing investment in R&D to 4.3% of revenue (2019: 2.9%); establishing Centres of Excellence; setting up a Global Business Services centre and disposal of the US Skincare product line.
  • Certain transformation initiatives were proactively re-phased given the COVID-19 backdrop - we spent $93 million on strategic operational investments in 2020.  We remain on track to deliver $130-$150 million of gross benefits in 2021.
  • Positive outlook: We expect to see 2021 organic4 revenue growth of between 3-4.5% and a constant currency adjusted EBIT margin of 18-19.5%.

 

Karim Bitar, Chief Executive Officer, commented:

“I am pleased with our strategic progress and how the business performed in 2020.  Against the backdrop of COVID-19 we set our new strategic direction of travel, responded well to the needs of our customers and improved our operational performance.  In addition our ongoing strategic transformation remains firmly on track. 

“The outlook for 2021 is positive although uncertainty surrounding COVID-19 persists.  We expect to see 2021 organic4 revenue growth of between 3-4.5% and a constant currency adjusted EBIT margin of 18-19.5% as we continue to invest in our transformation, some of which was deferred from 2020, and as COVID-suppressed costs begin to normalise.

“There is still further work ahead for the Group as we continue to strengthen our foundations and begin to pivot to sustainable and profitable growth, but I am confident in the inherent attractiveness of the markets we serve and in Convatec’s growth prospects.”

Group revenue

table

 

For insight into the category performances see pages 5 to 7.

 

(...)

Download the full text of this announcement

PDF Download

 

Analysts and Investors

ir@convatec.com

Kate Postans: Vice President of Investor Relations & Corporate Communications  

+44 (0)7826 447807

   

Media

 

Buchanan: Charles Ryland / Chris Lane   

+44 (0)207 466 5000

 

Press Release

See all

3/5/2022

Annual Results for the twelve months ended 31 December 2020

Read more

3/31/2021

Convatec awarded contract for Ostomy Products from Vizient, Inc.

Read more

4/29/2021

Trading update for the three months ended 31 March 2021

Read more

6/21/2021

Global commercial rights signed by Convatec Ltd for ChloraSolv, innovative wound debrider from RLS

Read more

7/30/2021

Interim Results for the six months ended 30 June 2021

Read more

9/30/2021

Convatec Group Plc Announces Offering of $500 Million Senior Notes due 2029

Read more

10/1/2021

Convatec Group Plc Announces Pricing of $500 Million 3.875% Senior Notes due 2029

Read more

5/13/2022

Trading update for the three months ended 30 September 2021

Read more

5/13/2022

Convatec awarded contract for Advanced Wound Care Products from Vizient, Inc.

Read more

5/13/2022

25 years of AQUACEL

Read more

5/13/2022

Chief Financial Officer succession

Read more